Cecilia Jones Sells 3,651 Shares of Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones sold 3,651 shares of the business’s stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $36.77, for a total value of $134,247.27. Following the completion of the transaction, the chief financial officer directly owned 33,870 shares of the company’s stock, valued at approximately $1,245,399.90. This trade represents a 9.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Agios Pharmaceuticals Stock Down 0.2%

NASDAQ AGIO opened at $40.07 on Thursday. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58. The firm has a market capitalization of $2.33 billion, a P/E ratio of 3.64 and a beta of 0.83. The company has a 50-day moving average price of $37.42 and a 200-day moving average price of $33.70.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The business had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.46 million. As a group, equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Hudson Bay Capital Management LP boosted its position in shares of Agios Pharmaceuticals by 17.4% in the second quarter. Hudson Bay Capital Management LP now owns 130,000 shares of the biopharmaceutical company’s stock worth $4,324,000 after purchasing an additional 19,280 shares during the period. Headlands Technologies LLC boosted its stake in Agios Pharmaceuticals by 18.0% in the 2nd quarter. Headlands Technologies LLC now owns 12,644 shares of the biopharmaceutical company’s stock worth $421,000 after purchasing an additional 1,929 shares during the period. Tower Research Capital LLC TRC boosted its stake in Agios Pharmaceuticals by 634.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,440 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 5,563 shares during the period. Two Sigma Securities LLC bought a new position in Agios Pharmaceuticals in the 2nd quarter worth approximately $288,000. Finally, Moore Capital Management LP boosted its stake in Agios Pharmaceuticals by 33.3% in the 2nd quarter. Moore Capital Management LP now owns 80,000 shares of the biopharmaceutical company’s stock worth $2,661,000 after purchasing an additional 20,000 shares during the period.

Wall Street Analyst Weigh In

AGIO has been the subject of several research reports. Bank of America reduced their price target on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Scotiabank reduced their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research report on Monday, July 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $56.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, September 4th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $56.00.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.